Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 81 - 86 of 86

Insights

Despite the huge task of implementing new serialisation technologies and processes, many pharmaceutical companies have delayed involving contract partners in their serialisation efforts, adopting a ‘wait and see’ approach.

Insights

Excipient selection strongly influences lyophilisation performance for biologic drugs.

Lyophilisation, or freeze drying, is a well-recognised method for delivering stable biologic drug products that have short shelf-lives in solution form.

Insights

As a result of increasing concerns over falsified medicines, reimbursement fraud and theft throughout the pharmaceutical supply chain, by 2019 over 55 countries will have introduced serialisation and track and trace regulations. With varying legislation coming into force across the globe, understanding the requirements of the markets you operate in is of paramount importance.

Insights

ABSTRACT: Glioblastoma remains an incurable brain cancer. Drugs developed in the past 20 years have not improved the prognosis for patients, necessitating the development of new treatments. We have previously reported the therapeutic potential of the quinoline methanol Vacquinol-1 (1) that targets glioblastoma cells and induces cell death by catastrophic vacuolization.

Insights

The many challenges faced by the pharmaceutical industry throughout the supply chain, including fraud and counterfeit medicines, have led to international serialisation requirements in the U.S and Europe. With this in mind, CDMOs have a lot to consider with the new track and trace regulations.

Insights

The risk of failure and cost invovled with developing new pharmaceutical products can be significantly reduced by using existing active ingredients in the development process and choosing the right partner for the development of the specific requirements of microtablets is crucial.